Recombinant Alkaline Phosphatase RecAP ARDS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute respiratory distress syndrome (ARDS) are inadequate, with high mortality rates and limited improvement in mortality or lung function, and there is a need for effective methods to preserve or improve respiratory function and shorten mechanical ventilation duration.
Innovation Solution
Administration of recombinant alkaline phosphatase (RecAP), specifically a chimeric form with high sequence identity to RecAP, in doses ranging from 500 U/kg to 2000 U/kg, to patients with severe or moderate ARDS, either due to sepsis or viral infections, to increase the partial pressure of arterial oxygen to fractional inspired oxygen ratio (P/F ratio) and reduce mechanical ventilation duration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mechanical ventilation is used to treat ARDS, then respiratory support is provided, but mortality rate remains high and lung function is not significantly improved
Solution Approach 1:
Alkaline phosphatase acts as a biochemical intermediary that modulates the inflammatory response in ARDS. The enzyme interacts with inflammatory mediators and cell signaling pathways to reduce lung inflammation and improve gas exchange, thereby addressing both mortality and lung function outcomes simultaneously
2Reliability
If high doses of alkaline phosphatase are administered, then P/F ratio and lung function improve, but treatment cost and complexity increase
Solution Approach 1:
The patent optimizes the dosage parameters of alkaline phosphatase administration, establishing specific dose ranges (500-2000 U/kg) and administration frequencies that achieve therapeutic efficacy while minimizing treatment complexity. This parameter optimization resolves the contradiction between improving P/F ratio and reducing treatment burden
3Reliability
If prolonged mechanical ventilation is used, then respiratory support is maintained, but duration of therapy and patient quality of life decrease
Solution Approach 1:
Alkaline phosphatase administration serves as a preliminary therapeutic intervention that accelerates lung recovery and reduces inflammation before mechanical ventilation can be safely discontinued. This preliminary action on the inflammatory pathway enables earlier weaning from ventilator support, thus reducing ventilation duration while maintaining respiratory support reliability
Data Source
AI summary
The present disclosure relates to the use of alkaline phosphatases, and in particular improved alkaline phosphatases such as RecAP, for the prevention, treatment, cure, or amelioration of the symptoms of acute respiratory distress syndrome (ARDS). The application relates to methods of preserving lung function, shortening the duration of mechanical ventilation therapy, increasing a the P/F ratio.